0:00:00my name aside can vary and i'm a felon he mythology and an ecology at
0:00:04the man clinical rochester
0:00:06and then assistant professor of madison
0:00:09and quality of the male clinic college of madison
0:00:12i'll be discussing a recent paper entitled at you can for plastic leukaemia and adolescents
0:00:17and young adults from genomics to the clinics
0:00:21the seen your author of this paper is doctor marked with so
0:00:25you'd look for plastic looking man and all sensing younger adults
0:00:28represents a unique and challenging disease and data for multiple reasons
0:00:33this by there is an improvement in survival in this population
0:00:37is still lagging behind compared to the excellent your rates in paediatric a well
0:00:43a reason analysis of this year database
0:00:46sure that the five year survival in this population was only sixty three percent compared
0:00:51to eighty seven percent in children up to fifteen years of age
0:00:55the reasons for this significant difference in survival are complex and not fully understood
0:01:02there are substantial differences in disease biology response to chemotherapy
0:01:07role of religion extends all transplantation
0:01:11and novel therapy you know this group
0:01:15several biological differences between paediatric i l and l and adolescents and young adults have
0:01:21been described
0:01:23first of all
0:01:24genetic alterations associated with good prognosis
0:01:29so it's just for hyper deplore d and trance location twelve twenty one
0:01:34bikinis in frequency with age well tourist site again ticks increasing prevalence
0:01:40in addition to that even good risk side the genetics such as type are deployed
0:01:45be
0:01:46are associated with inferior outcomes
0:01:48and adolescents and young adults compared to their counterpart in children
0:01:55patients between fifteen and thirty years of age have higher rates
0:02:00of
0:02:01minimal residual disease burden after chemotherapy compared to children
0:02:09there is also higher incidence of
0:02:12early precursor t cell a low
0:02:15and adolescents and young adults
0:02:17which is generally defined and eighty characterized by inferior outcomes and poor response to chemotherapy
0:02:24several studies have reported the genomic profiling and bit in paediatric patients with a well
0:02:31well no focus genomic analysis of idle sensing younger adults has been performed
0:02:36these patients what are frequently included in paediatric studies
0:02:41their genetic profile was similar to patients with high risk a l
0:02:47for example
0:02:48jack mediation
0:02:49intra chromosome amplification of chromosome twenty one
0:02:54and b c r a b a like a level where frequent findings
0:03:00in addition to the difference in biology
0:03:03between paediatric a allow and l and adolescents and young adults
0:03:08several analyses have shown survival benefits
0:03:11when these patients are treated on paediatric intense compared to adult protocols
0:03:17the reasons for this are not clear and likely to be mode a factorial
0:03:22including
0:03:23earlier introduction of c n as direct if the wrapping paediatric protocols
0:03:28the use of more intense chemotherapy
0:03:31and higher rates of compliance one adolescents are treated on paediatric protocols under the parents
0:03:37supervision
0:03:39the role of a logit mixed them so transplantation and adolescents and young adults with
0:03:44a l is also controversial
0:03:48there have been a prospective trials addressing this group
0:03:52and subgroup analyses
0:03:54from a little transplant trials have been controversial
0:03:58and finally with the emergence of novel therapies and at all day l
0:04:04i dollar sense and younger adults
0:04:05are frequently included
0:04:08in this clinical trials
0:04:10they seem to experience benefit from such approaches
0:04:14for example they benefited the most from a high degree talks a madman a pretty
0:04:18be al
0:04:20in early study is
0:04:22in a two zone a poser got my as in
0:04:24cluster opinion and their libyan
0:04:27have also want to have activity
0:04:30in early clinical trials and adolescents and young adult